India’s hospital and pharmaceutical sectors are shifting toward a technology-led growth model. Hospitals expect 10-15% growth in FY27, while pharma firms target 5-15% as they focus on specialty drugs and manufacturing expansion.
The Indian healthcare and pharmaceutical industries are entering a new phase of development. Instead of focusing solely on adding volume, major players are now prioritizing technology and specialized care to drive their next leg of expansion. This strategic shift is being supported by improved digital infrastructure, higher insurance penetration, and a focus on advanced medical treatments.
Hospital Sector Expansion Plans
For the hospital industry, the outlook for the fiscal year 2027 points toward a growth rate of 10% to 15%. This anticipated growth is largely supported by private equity interest and internal capital spending on infrastructure. Companies are increasingly investing in specialized medical facilities, such as robotic-assisted surgery and organ transplant units, to differentiate their services. Data indicates that a significant majority of hospitals are now integrating modern enterprise systems and preparing for digital connectivity with government health platforms like the National Health Claims Exchange. With the current hospital bed density standing at 1.6 per 1,000 people, there remains considerable room for expansion, especially in regions beyond India's largest cities.
Pharmaceutical Industry Focuses on Innovation
The pharmaceutical sector is also projecting growth between 5% and 15% for FY27. Beyond traditional generic drug manufacturing, companies are moving toward higher-value products, including biologics, biosimilars, and new chemical entities. This shift is intended to capitalize on global opportunities, such as the upcoming patent cliff, where billions of dollars in older drug patents are set to expire, creating space for generic and biosimilar manufacturers. Approximately 55% of pharmaceutical leaders are planning to increase their manufacturing capacity by 10% to 30% over the next three years to meet this anticipated global demand.
Evolving Healthcare Economics
Recent years have seen a positive change in how healthcare is funded in India. Out-of-pocket expenditure—the amount individuals pay directly for their treatment—has decreased from over 60% in FY15 to below 40% in recent data. This improvement is primarily driven by wider insurance coverage, which provides a more stable revenue base for organized hospital chains. While these trends suggest a positive outlook, companies must navigate the complexities of high capital expenditure requirements for new facilities and the intense competition in both the domestic and export pharma markets. Investors may monitor how effectively these companies manage their debt levels while funding these large-scale expansions and whether the actual demand for specialty treatments matches current aggressive investment plans.